Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Reaffirmed by Cantor Fitzgerald
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $150.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential downside of 39.42% from the stock’s current price. A number […]
More Stories
Inter Miami-PSG brings Lionel Messi reunion at Club World Cup
By Lizzy Beckerano ATLANTA — Inter Miami have already defied expectations at the 2025 FIFA Club World Cup, managing two draws against Al Ahly and Palmeiras plus...
Trump Says He Will Only Appoint Fed Chair Who Wants to Cut Interest Rates
By Aldgra Fredly President Donald Trump said on Friday that he may appoint someone who is more inclined to lower...
Western Battery Technology Aims to Leapfrog China’s Mineral Dominance
By Owen Evans China’s stranglehold on the battery market could be loosened with emerging technology that substitutes hard-to-source minerals with...
Pumpkin Power: Boost Immunity, Regulate Blood Sugar, and Protect Eye Health
By Ellen Wan Pumpkin is rich in functional ingredients and nutrients and offers many potential health benefits. Both scientific research...
GAMMA Investing LLC Raises Position in Eaton Corporation, PLC (NYSE:ETN)
GAMMA Investing LLC raised its position in Eaton Corporation, PLC (NYSE:ETN – Free Report) by 0.7% during the 1st quarter,...
Bristol Myers Squibb Company (NYSE:BMY) Shares Sold by Spire Wealth Management
Spire Wealth Management reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 1.6% in...